Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024PRNewsWire • 04/24/24
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferencePRNewsWire • 03/28/24
Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 03/12/24
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate UpdatesPRNewsWire • 03/12/24
Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 03/07/24
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024PRNewsWire • 02/28/24
All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong BuyZacks Investment Research • 02/06/24
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue ProceduresPRNewsWire • 01/24/24
Heron Therapeutics (HRTX) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 01/15/24
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative PainPRNewsWire • 01/07/24
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial GuidancePRNewsWire • 11/14/23